Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They’re also holding some other great biotech companies IMO…
Interesting enough, they show having a 126k share stake in ANVS, but no stake in AVXL nor SAVA
AIGH Capital Management LLC appears to have the largest stake, of the 20 new buyers
316,945 shares
Finitel.io shows (as of today) 23 institutional owners total, all holding long positions…
13.93%
of which 20 were new buyers in July & August.
Great overview, especially your rationale. Thank you
Great recap—thank you. It appears this is all coming together. Exciting. And before we know it, 2022 will be around the corner, on our doorstep(s)
Wow... I didn’t realize Dr. Tuchman was the previous CMO of Oncolytics Biotech—that’s impressive (one day that company is going to be a major player in Cancer therapies).
Also, like that Hayden IR is providing some investor relations services, including strategic marketing & presentation materials, etc. Excellent.
That would be huge, any one of those scenarios (fingers crossed & hoping one moves forward soon)
Agree. And would be fantastic to see an increase in (additional) collaboration moving forward
I concur.
Now sell that ARWR and take 1/4 of your gains and reinvest into SNPX before more good PR comes, and starts driving demand & the share price “north of 40” lol
I remember back in early Nov. 2016 when the FDA halted the ARC-520 Phase llb study due to primate deaths from toxicity using Ex1 synthetic delivery. And Arrowhead declined to comment about the deaths. They dismissed it all, since the deaths were “non-human.” Lucky for them, most Americans were focused on the presidential election during that time to distract media attention away from this incident. Nonetheless, I lost respect for them because of that.
Each to their own.
Why wouldn’t you (email) ask Neil Cataldi and/or Robert Weinstein rather than someone on ihub?
Or look up the company’s January 21, 2021 8-K yourself? Then you can read about the Pre-Funded & Broker warrants too.
Seriously though, I’m not concerned with future dilution with this company, because it was never an issue in the past.
And why are you so stoked with Arrowhead Pharmaceuticals? Are you selling some ARWR to buy some SNPX
Absolutely!!! And gives more incentive to increase one’s position, before the share price inevitably increases into double digits
Finally! Now let’s get this moving forward, so we can start helping those in need (which could be any one of us, as we get older)
Yup... fun stuff. End of the day, it’s promising to see the reawakening of Biotech, as the population ages, and Baby Boomers transition into their Golden Years “Don’t let me hear you say life’s taking you nowhere, whop, whop, whop.” Or should I say, “pop, pop, pop?” lol
Who doesn’t like a little Bowie in the morning with their coffee & Cheerios
Seems like the result of Robinhood Retail investors... from my online reading, they are embracing the biotech space, focusing on shorted stock. Of course, this is combined with lots of day & position trading. In some of the chat rooms, people are even asking their colleagues to treat SAVA as the next GameStop and support the buying frenzy. Perhaps Synaptogenix and even ProMIS Neurosciences will be on the radar of the hype, since these 2 companies are the most promising Alzheimer’s plays that could actually make significant improvements for those ravaged by the disease. Investing in both at these rock-bottom prices, will be very rewarding when the time comes. But in the meantime, it seems random on which biotech(s) pops here & there.
Yes it is — crazy (I guess crazy days are here). Congratulations on you Anavex investment. Cheers
Even vTv Therapeutics (VTVT) is up 32% After Hours, as Retail investors are looking for Alzheimer’s stock to jump into... We need to be on the Nasdaq to become visible as a speculative play for Retail, and take advantage of this frenzy of blind momentum. Or we need the company to start marketing its potential and create a plume of smoke to attract attention. But, (I know) we’re too scientific & clinical over here, and want the data to do all the talking, and eventually it will. Then we will become a supernova (from $2–$5 range to $500 overnight). KAPOW! Dr. Alois Alzheimer would be proud. Then eventually $1,906 / share (now that’s synaptic symbolism)
Agree. And... Seems ridiculous that Cassava share price is this high — where’s Adam Feuerstein & his typical Statnews articles giving clinical insight & calling bullshit on sub-par studies, such as this? And now Anavex too, riding on the coattail of Cassava. Just makes me shake my head. Wow, the marketplace is a whole new beast of blind momentum these days.
Doesn’t make any sense? Do I sound cynical... lol
Excellent points. Current share price is a gift for those that have done their DD. Financial freedom will follow.
I concur. Likely its last kick at the can, so will either wither & fade away, or BOOM! — propelled skyward as a key marketplace competitor in the Alzheimer’s space (where the latter is more likely IMO)
I like your observations. Will be interesting to see how this plays out in the next 6 months.
Maybe in 12 months from now, with good results, snpx will reach $175 to $250/share.
In all seriousness, if clinical results are extremely promising for any small biotech pursuing Alzheimer’s & Parkinson’s, I would expect that company to be bought out by Big Pharma
The SAVA press release of Simufilam’s interim results accentuates that a quality Alzheimer’s drug is still of huge interest for the investment community.
However, it also shows an overreaction IMO
$71 a share at this moment — seriously?
It may not even be first to market, never mind best-in-class. Not to be skeptical, but there’s a potential for a huge pullback in the coming months (resulting in some over paid shares). Yikes
I remember when SAVA used to be PTIE - Pain Therapeutics. A $10,000 investment in PTIE from 2011 to 2019 ended in $360 (-96.4% losses for its long investor).
Now it has reinvented itself, with similar price swings to its PTIE years. Hopefully this time it can bring superior rewards for those supporting its pipeline development.
Good insight. Like the idea of raising more cash...
Likely related to their newly hired Chief Clinical Development Officer, Dr. Kupiec (who came from ProMIS Neurosciences, and was their Chief Medical Officer)
Makes me wonder how strategic this hire is—
Perhaps, in a few months we’ll see an official partnership between Cassava Sciences & ProMIS Neurosciences, or possibly a buyout in order to create a dominant force in Alzheimer’s, Parkinson’s and ALS.
Thoughts?
Yes, onward & upward (and I guess we start getting reacquainted with our patience). This is now in growth mode.
Agree. ProMIS Neurosciences already analyzed big pharma Alzheimer’s data from the previous studies, over the years, showing the limitation (basically, the rabbit hole) of focusing on amyloid plaque... Too bad for Eli Lilly (wasting financial resources).
Perhaps next week? they may announce offering. ie. 10 million shares @ $2 to raise 20M, or something in that range. The sooner they do an offering, the better — and they shouldn’t need to get greedy with it. Thoughts?
I hope all investors here, are well rewarded & validated for their support in this science and desire to give Alzheimer’s patients an improved qualify of life.
It is interesting that the SP is moving, yet the trading volume is soft. Moreover, I see a few users IDs on the Yahoo Finance Conversation board for snpx, pumping the stock—that is disappointing. Makes me skeptical of what’s happening behind the scenes.
Thanks for the reply & insight
Is there any expected catalysts before August? Does anyone know if there’s a partnership discussion happening? Or non-dilutive financing being pursued? Don’t mind waiting, but would be nice if the company updated their website with a current company deck (corporate overview) presenting timelines & objectives to grow shareholder value.
Not betting the farm, but have accumulated a new sizeable position over the past few weeks—now in hold & wait mode. May some good fortune show itself...
I thought I would keep a small position, but I ended up getting out 3 weeks ago, and will revisit in the early spring 2021 to see where Neurotrope’s at (not that anyone cares about our positions)
Nonetheless, appears to be some smart people on this ihub board.
So my question is has anyone been following Moderna (MRNA) over the past year, or two? If so, what’s your thoughts on their trial design for COVID? Doesn’t it seem odd that their trial structure ignores non-symptomatic carriers & transmission in its methodology? That it’s designed only to use self diagnosed symptoms (that continue beyond 48 hours) to trigger blood work collection & COVID testing, rather than use their warp speed boatload of money to test all participants, regardless of symptoms.
Also, why not use a double-blind approach, instead of 1:1 randomization?
Thoughts?
Very true... and I have the patience required to be invested here, rooting for NTRP (soon to be NBI)
Good points (as to be expected in your commentaries)
With BIIB’s Aducanumab FDA approved, this translates into excellent news for ProMIS Neurosciences’ PMN310 going into 2021, as previously discussed last week. PMN310 data indicates it being far more superior than Aducanumab. Hence, might be worth adding to your Watchlist of other AD companies, incase you are (or anyone is) looking to diversify his/or her speculative AD plays.
Cheers
Ps. Looking forward to this merger being complete and NBI becoming a separate entity
Fantastic. Cheers
I hear you. I like Dr. Alkon, too
I’ll probably re-establish a small position next week and let it unfold however it does, rather than sit on the sidelines waiting and seeing—I’m diversified enough now to do that
Enjoy your weekend